Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue.
Alyssa HalperBelen SanchezJames S HodgesDonald R DengelAnna PetrykKyriakie SarafoglouPublished in: Clinical endocrinology (2019)
Anastrozole significantly reduced bone age advancement in children with CAH and advanced bone age (>2SDs) without adverse effects on BMD or VAT. Longitudinal studies of anastrozole in children with CAH are needed to validate these findings.